JP2001508430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001508430A5 JP2001508430A5 JP1998530400A JP53040098A JP2001508430A5 JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5 JP 1998530400 A JP1998530400 A JP 1998530400A JP 53040098 A JP53040098 A JP 53040098A JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Description
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/779,767 US6737057B1 (en) | 1997-01-07 | 1997-01-07 | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| US08/779,767 | 1997-01-07 | ||
| PCT/US1998/000520 WO1998030706A1 (en) | 1997-01-07 | 1998-01-07 | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001508430A JP2001508430A (ja) | 2001-06-26 |
| JP2001508430A5 true JP2001508430A5 (ja) | 2005-09-08 |
Family
ID=25117492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53040098A Ceased JP2001508430A (ja) | 1997-01-07 | 1998-01-07 | 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6737057B1 (ja) |
| EP (1) | EP1012308A1 (ja) |
| JP (1) | JP2001508430A (ja) |
| AU (1) | AU744885B2 (ja) |
| CA (1) | CA2277582A1 (ja) |
| WO (1) | WO1998030706A1 (ja) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020081298A1 (en) * | 1997-01-07 | 2002-06-27 | Habib Zaghouani | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| CA2331771A1 (en) * | 1998-07-06 | 2000-01-13 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| CA2340085A1 (en) * | 1998-08-10 | 2000-02-24 | Chiron Corporation | Engineered antigen-presenting cells expressing an array of antigens and uses thereof |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| JP2003514828A (ja) * | 1999-10-27 | 2003-04-22 | セル−サイ・コーポレーシヨン | 自己免疫および移植組織に関連する宿主対移植片症状の処置に有用なペプチド構築物の調製法および組成物 |
| EP1598370A3 (en) * | 1999-10-27 | 2006-05-10 | Cel-Sci Corporation | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions |
| DE60123238T2 (de) * | 2000-06-05 | 2007-05-03 | University of Tennessee Corp., Knoxville | Zusammensetzungen zur behandlung von autoimmunkrankheiten |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US8609091B2 (en) | 2002-04-09 | 2013-12-17 | The Curators Of The University Of Missouri | Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes |
| US8603472B2 (en) * | 2002-04-09 | 2013-12-10 | The Curators Of The University Of Missouri | Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide |
| AU2003230830A1 (en) | 2002-04-09 | 2003-10-27 | The Curators Of The University Of Missouri | Treatment of type 1 diabetes before and after expression of predisposition markers |
| US7744876B2 (en) | 2002-04-09 | 2010-06-29 | The Curators Of The University Of Missouri | Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes |
| US8603471B2 (en) * | 2002-04-09 | 2013-12-10 | The Curators Of The University Of Missouri | Methods and compositions for preventing the onset of type 1 diabetes |
| CA2526950C (en) * | 2002-05-27 | 2012-06-26 | Leif Hakansson | Method for determining immune system affecting compounds |
| AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| SE0402536D0 (sv) | 2004-10-20 | 2004-10-20 | Therim Diagnostica Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
| US8110347B2 (en) * | 2005-04-15 | 2012-02-07 | Canimguide Therapeutics Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6 |
| EP2226334A3 (en) | 2007-05-08 | 2010-12-29 | CanImGuide Therapeutics AB | Immunoregulatory structures from normally occuring proteins |
| EP2421896A1 (en) | 2009-04-22 | 2012-02-29 | Merck Patent GmbH | Antibody fusion proteins with modified fcrn binding sites |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 赤血球結合療法 |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| AU616338B2 (en) | 1989-02-02 | 1991-10-24 | Mato Maschinen- Und Metallwarenfabrik Curt Matthaei Gmbh & Co Kg | Belt skimming device |
| JP3355351B2 (ja) * | 1989-02-24 | 2002-12-09 | ユーロジェン・ホールディング・ソシエテ・アノニム | 遺伝的に工作されたイムノグロブリン |
| US5612035A (en) | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
| WO1993006135A1 (en) | 1991-09-23 | 1993-04-01 | Genentech, Inc. | Diagnosing and treating autoimmune disorders |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| AU3220593A (en) | 1991-11-19 | 1993-06-15 | Anergen, Inc. | Soluble mhc molecules and their uses |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| WO1994014847A1 (en) | 1992-12-24 | 1994-07-07 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5820866A (en) | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
| US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| CA2218858A1 (en) | 1995-05-02 | 1996-11-07 | Alexion Pharmaceuticals Inc. | Modified myelin protein molecules |
| US20020081298A1 (en) * | 1997-01-07 | 2002-06-27 | Habib Zaghouani | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| EP1007567A4 (en) | 1997-08-19 | 2005-03-16 | Sinai School Medicine | CLASS II ELEMENT OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CARRYING AN EPITOPE / IMMUNOGLOBULIN CHIMERIC MOLECULES |
-
1997
- 1997-01-07 US US08/779,767 patent/US6737057B1/en not_active Expired - Fee Related
-
1998
- 1998-01-07 EP EP98901773A patent/EP1012308A1/en not_active Withdrawn
- 1998-01-07 CA CA002277582A patent/CA2277582A1/en not_active Abandoned
- 1998-01-07 AU AU58214/98A patent/AU744885B2/en not_active Ceased
- 1998-01-07 WO PCT/US1998/000520 patent/WO1998030706A1/en active IP Right Grant
- 1998-01-07 JP JP53040098A patent/JP2001508430A/ja not_active Ceased
-
2004
- 2004-05-17 US US10/847,139 patent/US20060034864A1/en not_active Abandoned